Neutralizing antibodies against Plasmodium falciparum associated with successful cure after drug therapy
Goh Y.S. Peng K. Siau A. Chotivanich K. Gruner A.-C. Preiser P. Mayxay M. Pukrittayakamee S. Sriprawat K.
Goh Y.S.
Peng K.
Siau A.
Chotivanich K.
Gruner A.-C.
Preiser P.
Mayxay M.
Pukrittayakamee S.
Sriprawat K.
An error occurred retrieving the object's statistics
Citations
Altmetric:
Alternative Title
Abstract
An effective antibody response can assist drug treatment to contribute to better parasite clearance in malaria patients. To examine this, sera were obtained from two groups of adult patients with acute falciparum malaria, prior to drug treatment: patients who (1) have subsequent recrudescent infection, or (2) were cured by Day 28 following treatment. Using a Plasmodium falciparum antigen library, we examined the antibody specificities in these sera. While the antibody repertoire of both sera groups was extremely broad and varied, there was a differential antibody profile between the two groups of sera. The proportion of cured patients with antibodies against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 was higher than the proportion of patients with recrudescent infection. The presence of these antibodies was associated with higher odds of treatment cure. Sera containing all six antibodies impaired the invasion of P. falciparum clinical isolates into erythrocytes. These results suggest that antibodies specific against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 in P. falciparum infections could assist anti-malarial drug treatment and contribute to the resolution of the malarial infection. © 2016 Goh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
artemether plus benflumetol, artesunate, azithromycin, EBA181 antibody, EXP1 antibody, GLURP antibody, MSP3 antibody, neutralizing antibody, parasite antigen, RAMA antibody, SEA antibody, unclassified drug, antimalarial agent, antiserum, artemether, artemisinin derivative, azithromycin, benflumetol, EBA-181 protein, Plasmodium falciparum, ethanolamine derivative, fluorene derivative, glutamate-rich protein, Plasmodium, merozoite surface protein 3, Plasmodium, neutralizing antibody, parasite antigen, protozoal protein, protozoon antibody, QF116 antigen, Plasmodium falciparum, adult, antibody response, antibody specificity, Article, clinical article, erythrocyte, human, human cell, malaria falciparum, merozoite, molecular library, nonhuman, parasite clearance, parasite isolation, Plasmodium falciparum, species invasion, acute disease, adolescent, biosynthesis, blood, cohort analysis, drug effects, female, genetics, growth, development and aging, humoral immunity, immunology, Malaria, Falciparum, male, parasitology, Plasmodium falciparum, recurrent disease, treatment outcome, Acute Disease, Adolescent, Adult, Antibodies, Neutralizing, Antibodies, Protozoan, Antibody Specificity, Antigens, Protozoan, Antimalarials, Artemisinins, Azithromycin, Cohort Studies, Erythrocytes, Ethanolamines, Female, Fluorenes, Humans, Immune Sera, Immunity, Humoral, Malaria, Falciparum, Male, Plasmodium falciparum, Protozoan Proteins, Recurrence, Treatment Outcome
Source Title
PLoS ONE
Publisher
Series/Report No.
Collections
Rights
Attribution 4.0 International
Date
2016
DOI
10.1371/journal.pone.0159347
Type
Article